BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

12.63B

Market cap12.63B

Price-Earnings ratio

43.78

Price-Earnings ratio43.78

Dividend yield

—

Dividend yield—

Average volume

2.16M

Average volume2.16M

High today

$65.48

High today$65.48

Low today

$62.00

Low today$62.00

Open price

$64.85

Open price$64.85

Volume

4.37M

Volume4.37M

52 Week high

$66.28

52 Week high$66.28

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

With a market cap of 12.63B, BioMarin(BMRN) trades at $62.00. The stock has a price-to-earnings ratio of 43.78.

On 2026-08-09, BioMarin(BMRN) stock moved within a range of $62.00 to $65.48. With shares now at $62.00, the stock is trading 0.0% above its intraday low and -5.3% below the session's peak.

Trading volume for BioMarin(BMRN) stock has reached 4.37M, versus its average volume of 2.16M.

The stock's 52-week range extends from a low of $49.26 to a high of $66.28.

BMRN News

Simply Wall St 2h

BioMarin Is Up 6.3% After Raising 2026 Revenue Guidance And Highlighting Voxzogo Momentum

In early August 2026, BioMarin Pharmaceutical reported second-quarter revenue of US$989.71 million, raised its full-year 2026 revenue guidance range, and issued...

Simply Wall St 1d

BioMarin Stock Gains On Higher Outlook Despite Profit Drop - simplywall.st

...

TipRanks 2d

BioMarin price target raised to $86 from $80 at BofA

BofA analyst Jason Zemansky raised the firm’s price target on BioMarin (BMRN) to $86 from $80 and keeps a Buy rating on the shares. BioMarin’s Q2 was a beat and...

Analyst ratings

76%

of 29 ratings

Buy

75.9%

Hold

24.1%

Sell

More BMRN News

TipRanks 2d

BioMarin Buy Rating Reaffirmed as Strong Voxzogo Performance and Pipeline Progress Support Durable Growth; $94 Price Target Maintained

Wedbush analyst Yun Zhong maintained a Buy rating on BioMarin Pharmaceutical today and set a price target of $94.00. Unlock powerful investing tools with TipRa...

Simply Wall St 2d

BioMarin Pharmaceutical Could Be 30% Below Fair Value On Raised Guidance

BioMarin Pharmaceutical (BMRN) has just released its second quarter 2026 results, giving investors fresh detail on how revenue, earnings and guidance are evolvi...

TipRanks 3d

BioMarin reports Q2 non-GAAP EPS $1.20, consensus 95c

Reports Q2 revenue $990M, consensus $932.04M. “This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin’s (BMRN) o...

Simply Wall St 4d

Novo Nordisk Stock Shock Has Investors Rethinking Obesity Drug Exposure

The recent pullback in Novo Nordisk stock after its guidance update has put a harsh spotlight on obesity and metabolic disorder therapeutics. The market reactio...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.